CuraFi embeds AI-powered decision support within the EMR to guide providers toward accurate coding, in-network referrals, and cost-effective therapies. The platform utilizes proprietary drug intelligence and machine learning models to benchmark drug utilization and predict cost changes for risk-bearing organizations. This integration optimizes clinical choices to lower costs and streamline care coordination at the point of service.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Healthcare providers and plans face increasing pressure to manage rising drug costs, especially with the shift in risk introduced by the Inflation Reduction Act (IRA). The loss of rebate revenue from CMS-negotiated Maximum Fair Price (MFP) drugs, increased drug utilization due to copay smoothing, and the elimination of the coverage gap contribute to escalating expenses.
Solution
CuraFi offers an AI-driven risk analysis and cost management platform designed to help healthcare providers and plans control drug spending. The platform identifies opportunities for savings by addressing the coverage gap created by the IRA changes, including copay smoothing, catastrophic reinsurance, and managing MFP drugs. CuraFi benchmarks data against comparable plans to pinpoint over/under-indexed drugs and provides strategic support for upcoming bids. By enabling better management of Part B to Part D shifts and promoting biosimilar utilization, CuraFi guarantees savings on drug spend.
Target Audience
CuraFi targets health plans and provider groups/ACOs seeking to control drug costs and manage risk effectively.
Features
- AI-driven risk analysis to identify drug savings opportunities.
- Benchmarking data against comparable plans to pinpoint over/under-indexed drugs.
- Strategic support for managing copay smoothing, catastrophic reinsurance, and MFP drugs under the IRA.
- Facilitation of Part B to Part D shifts for cost optimization.
- Promotion of biosimilar utilization to reduce drug expenses.
- Guaranteed savings on drug spend.